HIVID
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIVID is an oral small-molecule antiviral tablet approved by Roche in 1992 for HIV treatment. The drug represents an early nucleoside reverse transcriptase inhibitor class therapeutic developed during the initial wave of antiretroviral therapy. Specific mechanism of action and indication details are not documented in available records.
LOE Approaching
This product is in late-stage lifecycle with minimal current commercial activity, indicating limited expansion opportunities and likely small team presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
225 enrolled
HIV Infections
A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
528 enrolled
HIV Infections
Career Relevance
HIVID offers zero linked job opportunities, reflecting its post-LOE status and minimal commercial presence. Career development on this product is limited to legacy portfolio management or regulatory wind-down activities.
Product Manager (legacy portfolio)
Worked on HIVID at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.